Single dose nivolumab and ipilimumab treatment causing complete and durable response in extensive stage - small cell lung cancer complicated by severe sensory autoimmune neuropathy

Authors

Aaron Lobo MD, Yale New Haven Health/Bridgeport Hospital
Nur Rahman MD, Yale New Haven Health/Bridgeport Hospital
Nicholas Blondin MD, Yale University
Neal Fischbach, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut.

Document Type

Conference Proceeding

Abstract

The use of immune checkpoint inhibitors (ICI) in recent years has increasingly emerged as a second-line treatment in the management of extensive-stage small cell lung cancer (ES-SCLC) compared to conventional chemotherapy alone.

The use of combined ICI therapy by inhibiting two distinct pathways in patients with ES-SCLC has been evaluated in clinical trials. The increase incidence of immune related adverse events (Ir-AE) in these trials due to excessive immune system activation or multiple organ disorders has posed serious clinical challenges.

Here we report a dramatic and durable response to combined immune checkpoint blockade without chemotherapy and discuss the relationship between severe ICI toxicity and durable response as well as potential role of anti-neuronal antigen immune activation producing profound anti-tumor effect but also leading to severe autoimmune toxicity

Publication Date

Spring 2025

Comments

Presented at: NCCN 2025

Recommended Citation

Lobo, Aaron MD; Rahman, Nur MD; Blondin, Nicholas MD; and Fischbach, Neal, "Single dose nivolumab and ipilimumab treatment causing complete and durable response in extensive stage - small cell lung cancer complicated by severe sensory autoimmune neuropathy" (2025). Posters. 65.
https://scholar.bridgeporthospital.org/poster_presentations/65